Vaxcyte, Inc.
PCVX
$59.42
-$0.94-1.56%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 34.93M | 33.07M | 32.22M | 32.45M | 32.04M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 302.78M | 345.85M | 274.28M | 242.38M | 226.22M |
| Operating Income | -302.78M | -345.85M | -274.28M | -242.38M | -226.22M |
| Income Before Tax | -284.30M | -320.62M | -246.51M | -212.83M | -166.57M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -284.30M | -320.62M | -246.51M | -212.83M | -166.57M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -284.30M | -320.62M | -246.51M | -212.83M | -166.57M |
| EBIT | -302.78M | -345.85M | -274.28M | -242.38M | -226.22M |
| EBITDA | -299.78M | -342.90M | -266.79M | -239.32M | -223.34M |
| EPS Basic | -1.97 | -2.30 | -1.81 | -1.56 | -1.22 |
| Normalized Basic EPS | -1.23 | -1.44 | -1.13 | -0.98 | -0.77 |
| EPS Diluted | -1.97 | -2.30 | -1.81 | -1.56 | -1.22 |
| Normalized Diluted EPS | -1.23 | -1.44 | -1.13 | -0.98 | -0.77 |
| Average Basic Shares Outstanding | 144.49M | 139.51M | 136.43M | 136.20M | 136.03M |
| Average Diluted Shares Outstanding | 144.49M | 139.51M | 136.43M | 136.20M | 136.03M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |